Indoco Remedies Crescita futura
Criteri Future verificati 4/6
Indoco Remedies prevede che gli utili e i ricavi cresceranno rispettivamente di 113% e 12.6% all'anno. Si prevede che l'EPS crescerà di 114.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.5% in 3 anni.
Informazioni chiave
113.0%
Tasso di crescita degli utili
114.17%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 16.0% |
| Tasso di crescita dei ricavi | 12.6% |
| Rendimento futuro del capitale proprio | 12.47% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 11 May 2026 |
Aggiornamenti recenti sulla crescita futura
The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Recent updates
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook
Analysts have raised their price target on Indoco Remedies from ₹207 to ₹250, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that together suggest a higher estimated fair value for the stock. What's in the News A board meeting is scheduled for April 30, 2026, to consider transferring Indoco Remedies' ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited, on terms set out in a business transfer agreement (Key Developments).Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Key Insights Indoco Remedies will host its Annual General Meeting on 11th of September Total pay for CEO Sundeep...Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
The Indoco Remedies Limited ( NSE:INDOCO ) share price has done very well over the last month, posting an excellent...Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Indoco Remedies Limited ( NSE:INDOCO ) shares have had a horrible month, losing 25% after a relatively good period...
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a mediocre week for Indoco Remedies Limited ( NSE:INDOCO ) shareholders, with the stock dropping 11% to ₹304...Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
A lackluster earnings announcement from Indoco Remedies Limited ( NSE:INDOCO ) last week didn't sink the stock price...Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Indoco Remedies Limited ( NSE:INDOCO ), which a week ago released some...Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Performance at Indoco Remedies Limited ( NSE:INDOCO ) has been reasonably good and CEO Sundeep Bambolkar has done a...Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2028 | 23,777 | 1,257 | 1,979 | 2,914 | 4 |
| 3/31/2027 | 21,091 | 721 | 2,273 | 3,520 | 2 |
| 3/31/2026 | 18,453 | -951 | 447 | 1,922 | N/A |
| 12/31/2025 | 17,599 | -1,139 | N/A | N/A | N/A |
| 9/30/2025 | 17,251 | -1,105 | -960 | 1,408 | N/A |
| 6/30/2025 | 16,713 | -1,122 | N/A | N/A | N/A |
| 3/31/2025 | 16,649 | -737 | -2,612 | 949 | N/A |
| 12/31/2024 | 17,243 | -107 | N/A | N/A | N/A |
| 9/30/2024 | 17,732 | 321 | -3,076 | 2,220 | N/A |
| 6/30/2024 | 18,223 | 767 | N/A | N/A | N/A |
| 3/31/2024 | 18,173 | 985 | -2,706 | 1,554 | N/A |
| 12/31/2023 | 17,958 | 1,016 | N/A | N/A | N/A |
| 9/30/2023 | 17,356 | 1,134 | -911 | 1,442 | N/A |
| 6/30/2023 | 16,869 | 1,281 | N/A | N/A | N/A |
| 3/31/2023 | 16,686 | 1,423 | -284 | 1,788 | N/A |
| 12/31/2022 | 16,496 | 1,569 | N/A | N/A | N/A |
| 9/30/2022 | 16,084 | 1,617 | 85 | 1,703 | N/A |
| 6/30/2022 | 15,622 | 1,537 | N/A | N/A | N/A |
| 3/31/2022 | 15,408 | 1,548 | 485 | 1,738 | N/A |
| 12/31/2021 | 14,368 | 1,393 | N/A | N/A | N/A |
| 9/30/2021 | 14,110 | 1,317 | 257 | 1,391 | N/A |
| 6/30/2021 | 13,524 | 1,157 | N/A | N/A | N/A |
| 3/31/2021 | 12,415 | 930 | 54 | 822 | N/A |
| 12/31/2020 | 12,084 | 734 | N/A | N/A | N/A |
| 9/30/2020 | 11,654 | 571 | 387 | 931 | N/A |
| 6/30/2020 | 11,298 | 393 | N/A | N/A | N/A |
| 3/31/2020 | 11,066 | 241 | 644 | 1,228 | N/A |
| 12/31/2019 | 10,909 | 302 | N/A | N/A | N/A |
| 9/30/2019 | 10,640 | 264 | N/A | N/A | N/A |
| 6/30/2019 | 10,071 | 111 | N/A | N/A | N/A |
| 3/31/2019 | 9,684 | -29 | N/A | 1,321 | N/A |
| 3/31/2018 | 10,424 | 412 | N/A | 1,227 | N/A |
| 3/31/2017 | 10,968 | 771 | N/A | 886 | N/A |
| 3/31/2016 | 10,081 | 819 | N/A | 1,122 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che INDOCO diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 6.9% ).
Guadagni vs Mercato: Si prevede che INDOCO diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede INDOCO diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di INDOCO ( 12.6% all'anno) crescerà più rapidamente del mercato Indian ( 10.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di INDOCO ( 12.6% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di INDOCO sarà basso tra 3 anni ( 12.5 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/21 21:44 |
| Prezzo dell'azione a fine giornata | 2026/06/19 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Indoco Remedies Limited è coperta da 11 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |